# GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

> **NCT03029351** · PHASE4 · TERMINATED · sponsor: **University at Buffalo** · enrollment: 15 (actual)

## Conditions studied

- Type2 Diabetes
- Kidney Diseases

## Interventions

- **DRUG:** Exenatide Extended Release for Inj Susp 2 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03029351
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-10
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** termination by sponsor
- **Last updated:** 2024-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029351, "GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03029351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*